Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1: Th2 cytokine ratios

Immunology

Volumn 105, Issue 1, 2002, Pages 56-62

  Wachholz, Petra A ^a   Nouri Aria, Kayhan T ^a   Wilson, Duncan R ^a   Walker, Samantha M ^a   Verhoef, Adrienne ^a   Till, Stephen J ^a   Durham, Stephen R ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; GAMMA INTERFERON; GRASS POLLEN EXTRACT; INTERLEUKIN 5; MESSENGER RNA; PLACEBO;

ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; GRASS POLLEN; HAY FEVER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; LYMPHOCYTE COUNT; NOSE MUCOSA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBITS AND HARES; RANDOMIZED CONTROLLED TRIAL; SEASONAL VARIATION; TH1 CELL; TH2 CELL; TREATMENT OUTCOME;

ANTIGENS, CD3; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; HUMANS; IN SITU HYBRIDIZATION; INTERFERON TYPE II; INTERLEUKIN-5; LEUKOCYTES, MONONUCLEAR; NASAL MUCOSA; POACEAE; POLLEN; RHINITIS, ALLERGIC, SEASONAL; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES; TH1 CELLS; TH2 CELLS;

EID: 0036164580     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2002.01338.x     Document Type: Article

References (44)

1. Allergy and allergic diseases (Part I)
2. Allergy and allergic diseases (Part II)
3. Cytokine messenger RNA expression for IL-3, IL-4, IL-5, and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after local allergen provocation: Relationship to tissue eosinophilla
4. IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatants
5. Evidence suggesting involvement of interleukin-4 (IL-4) production in spontaneous in vitro IgE synthesis in patients with atopic dermatitis
6. Relationships between natural T cells, atopy, IgE levels, and IL-4 production
7. T cells are the principal source of interleukin-5 mRNA in allergen-induced rhinitis
8. Activation of CD4+ T cells, increased Th2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma
9. Evidence for compartmentalization of functional subsets of CD2+ T lymphocytes in atopic patients
10. Human atopen-specific types 1 and 2 T helper cell clones
11. The relationship between infiltrating CD4+ lymphocytes, activated eosinophils, and the magnitude of the allergen-induced late phase cutaneous reaction in man
12. Eosinophil activation and T lymphocyte infiltration in allergen-induced late phase skin reactions and classical delayed-type hypersensitivity
13. Immunohistology of the nasal mucosa following allergen-induced rhinitis. Identification of activated T lymphocytes, eosinophils, and neutrophils
14. Allergen-stimulated interleukin-4 and interferon-gamma production in primary culture: Responses of subjects with allergic rhinitis and normal controls
15. IL-5 secretion by allergen-stimulated CD4+ T cells in primary culture: Relationship to expression of allergic disease
16. WHO position paper allergen immunotherapy: Therapeutic vaccines for allergic diseases
17. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs
18. Changes in allergic inflammation associated with successful immunotherapy
19. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity
20. Changes in nasal metachromatic cells during allergen immunotherapy
21. Grass pollen immunotherapy: Symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season
22. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium
23. Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy
24. IgG subclass antibody response in grass pollen-allergic patients undergoing specific immunotherapy. Prognostic value of serum IgG subclass antibody levels early in immunotherapy
25. Monitoring allergen immunotherapy of pollen-allergic patients: The ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome
26. Immunologic changes during immunotherapy in asthmatic children: Increased IL-13 and allergen-specific IgG4 antibody levels
27. Immunotherapy affects the seasonal increase in specific IgE and interleukin-4 in serum of patients with seasonal allergic rhinitis
28. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma
29. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses
30. Immunological changes during specific immunotherapy of grass pollen allergy: Reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Ph1, p. 1, a major grass pollen allergen
31. IL-5 production by allergen-stimulated T cells following grass pollen immunotherapy for seasonal allergic rhinitis
32. A biopsy method to obtain high quality specimens of nasal mucosa
33. Grass pollen immunotherapy for seasonal rhinitis and asthma: A randomized, controlled trial
34. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy
35. Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis
36. Cytokine production by peripheral blood mononuclear cells following birch-pollen immunotherapy
37. Changes in cytokine production in vitro during the early phase of birch-pollen immunotherapy
38. Long-term clinical efficacy of grass-pollen immunotherapy
39. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy
40. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro
41. Role of interleukin 10 in specific immunotherapy
42. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: Two key steps in specific immunotherapy
43. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation
44. T cells from human allergen-induced late asthmatic responses express IL-12 receptor beta 2 subunit mRNA and respond to IL-12 in vitro